Sunitinib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
91.73
Gini
0.524
CATDS
0.007
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Sunitinib. Strongest target: CAMK2D at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CAMK2D | 100.0% | 0.0% |
| 2 | MYLK4 | 99.1% | 0.9% |
| 3 | FLT3 | 98.7% | 1.3% |
| 4 | TNIK | 98.3% | 1.7% |
| 5 | ARK5_NUAK1 | 97.8% | 2.2% |
| 6 | KHS_MAP4K5 | 97.8% | 2.2% |
| 7 | GLK_MAP4K3 | 97.6% | 2.4% |
| 8 | RET | 97.2% | 2.8% |
| 9 | FMS | 97.1% | 2.9% |
| 10 | YES_YES1 | 96.6% | 3.4% |
| 11 | CAMK2A | 96.3% | 3.7% |
| 12 | HPK1_MAP4K1 | 96.3% | 3.7% |
| 13 | AMPK(A2_B2_G2) | 96.3% | 3.7% |
| 14 | LRRK2 | 95.8% | 4.2% |
| 15 | PHKG1 | 95.6% | 4.4% |
| 16 | TRKC | 95.4% | 4.6% |
| 17 | CHK2 | 95.0% | 5.0% |
| 18 | AMPK(A1_B2_G1) | 94.6% | 5.4% |
| 19 | AMPK(A1_B2_G2) | 94.5% | 5.5% |
| 20 | AMPK(A1_B2_G3) | 93.6% | 6.4% |
Selectivity landscape
Where Sunitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Sunitinib.
Atlas insights for Sunitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3155.87 | |
| ALLOGRAFT_REJECTION | 10247.27 | |
| ANDROGEN_RESPONSE | 2348.88 | |
| ANGIOGENESIS | 1800.49 | |
| APICAL_JUNCTION | 10768.75 | |
| APICAL_SURFACE | 986.03 | |
| APOPTOSIS | 8948.13 | |
| BILE_ACID_METABOLISM | 1236.89 | |
| CHOLESTEROL_HOMEOSTASIS | 1388.75 | |
| COAGULATION | 1164.98 | |
| COMPLEMENT | 5922.98 | |
| DNA_REPAIR | 2268.04 | |
| E2F_TARGETS | 6500.87 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2977.58 | |
| ESTROGEN_RESPONSE_EARLY | 4517.89 | |
| ESTROGEN_RESPONSE_LATE | 4335.13 | |
| FATTY_ACID_METABOLISM | 887.26 | |
| G2M_CHECKPOINT | 6464.53 | |
| GLYCOLYSIS | 4125.20 | |
| HEDGEHOG_SIGNALING | 1349.20 | |
| HEME_METABOLISM | 2587.29 | |
| HYPOXIA | 5437.55 | |
| IL2_STAT5_SIGNALING | 3295.50 | |
| IL6_JAK_STAT3_SIGNALING | 6426.01 | |
| INFLAMMATORY_RESPONSE | 5384.35 | |
| INTERFERON_ALPHA_RESPONSE | 890.46 | |
| INTERFERON_GAMMA_RESPONSE | 7648.24 | |
| KRAS_SIGNALING_DN | 1587.59 | |
| KRAS_SIGNALING_UP | 3789.64 | |
| MITOTIC_SPINDLE | 7686.19 | |
| MTORC1_SIGNALING | 4974.54 | |
| MYC_TARGETS_V1 | 3896.58 | |
| MYC_TARGETS_V2 | 984.68 | |
| MYOGENESIS | 4756.31 | |
| NOTCH_SIGNALING | 338.09 | |
| OXIDATIVE_PHOSPHORYLATION | 1581.66 | |
| P53_PATHWAY | 4711.77 | |
| PANCREAS_BETA_CELLS | 552.82 | |
| PEROXISOME | 1667.51 | |
| PI3K_AKT_MTOR_SIGNALING | 11320.05 | |
| PROTEIN_SECRETION | 2557.47 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 534.35 | |
| SPERMATOGENESIS | 2006.43 | |
| TGF_BETA_SIGNALING | 2618.16 | |
| TNFA_SIGNALING_VIA_NFKB | 5455.97 | |
| UNFOLDED_PROTEIN_RESPONSE | 2104.51 | |
| UV_RESPONSE_DN | 5894.09 | |
| UV_RESPONSE_UP | 4767.33 | |
| WNT_BETA_CATENIN_SIGNALING | 2813.20 | |
| XENOBIOTIC_METABOLISM | 2480.78 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.850 |
| SRR23303752 | — | 0.836 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.833 |
| aMVAC.P_005_TURBT_S223 | — | 0.824 |
| SRR10899984 | — | 0.823 |
Annotations
Sign in to read and post annotations.
Loading…